EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.708
https://www.valueinhealthjournal.com/article/S1098-3015(22)02912-6/fulltext
Section Title :
Section Order :
10245
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02912-6&doi=10.1016/j.jval.2022.09.708